NPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2
Date
2020
Type:
Article
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1,
MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Current Molecular Medicine, 2020, 20: 1-3
Keywords
COVID-19, SARS-Cov-2, Niemann-Pick C1, Modifier gene, Drug repurposing, Virus, Infection